Trials / Terminated
TerminatedNCT05399368
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- RAPT Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 study of RPT193 in adults with atopic dermatitis
Detailed description
Randomized, placebo-controlled Phase 2 study of RPT193 in adults with moderate-to-severe atopic dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPT193 | RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17 |
| OTHER | Placebo | Nonactive placebo tablet |
Timeline
- Start date
- 2022-06-07
- Primary completion
- 2024-05-24
- Completion
- 2024-05-24
- First posted
- 2022-06-01
- Last updated
- 2026-03-23
- Results posted
- 2026-02-25
Locations
59 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05399368. Inclusion in this directory is not an endorsement.